Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database

BACKGROUND: A randomized clinical trial has found that the addition of erlotinib to gemcitabine (GEM-E) for pancreatic cancer led to a modest increase in survival. The aim of this national population-based retrospective study was to compare the effectiveness of GEM-E to GEM alone for pancreatic canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Sangjin, Park, Chan Mi, Kwon, Hanbyeol, Lee, Kyung-Hun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940912/
https://www.ncbi.nlm.nih.gov/pubmed/27400734
http://dx.doi.org/10.1186/s12885-016-2482-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940912/
https://www.ncbi.nlm.nih.gov/pubmed/27400734
http://dx.doi.org/10.1186/s12885-016-2482-z

Ejemplares similares